Equity evaluations for clinical-stage biopharmaceutical companies like Compass Therapeutics depend heavily on ongoing drug pipeline trial updates, regulatory milestones, and cash burn rates. To evaluate this effectively: What is your overall portfolio risk tolerance, and what target allocation do you maintain for high-beta biotechnology equities?